Preferred Label : etesevimab;

Obsolete resource : false;

UNII : N7Q9NLF11I;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-atu-rtu/bamlanivimab-700-mg-20-ml-35-mg-ml-solution-a-diluer-pour-perfusion-etesevimab-700-mg-20-ml-35-mg-ml-solution-a-diluer-pour-perfusion-en-association
2021
false
false
false
France
French
drug therapy, combination
summary of product characteristics
package leaflet
guidelines for drug use
infusions, intravenous
adult
aged
bamlanivimab
etesevimab
COVID-19
antibodies, monoclonal, humanized

---
https://ansm.sante.fr/actualites/covid-19-lacces-aux-bitherapies-danticorps-monoclonaux-contre-la-covid-19-est-elargi
2021
false
false
false
France
French
drug information
drug combinations
antibodies, monoclonal, humanized
adult
Casirivimab/Imdevimab
Bamlanivimab
Etesevimab
guidelines for drug use
casirivimab
imdevimab
bamlanivimab
etesevimab
casirivimab and imdevimab drug combination
COVID-19
casirivimab and imdevimab drug combination
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)

---
https://splf.fr/wp-content/uploads/2021/03/SPILF-Place-des-combinaisons-danticorps-monoclonaux-dans-le-traitement-des-infections-a-SARS-COV2-23-03-21.pdf
2021
false
false
false
France
coronavirus infections
pneumonia, viral
etesevimab
scientific and technical information
infectious disease, nos
Infections
Infectious disease
monoclonal antibody
Monoclonal antibodies
antibodies, monoclonal
Monoclonal antibodies
combined
COVID-19

---
https://www.infectiologie.com/fr/actualites/combinaisons-d-ac-monoclonaux-en-traitement-du-sars-cov2_-n.html
2021
false
false
false
France
COVID-19
etesevimab
drug therapy, combination
infusions, intravenous
bamlanivimab
casirivimab
Casirivimab/Imdevimab
treatment outcome
imdevimab
scientific and technical information

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.